Clinical Trials Logo

Clinical Trial Summary

This is a single-arm, single-centre phase II study to evaluate the efficacy (PFS, ORR, DCR) and safety of recombinant human adenovirus type 5 in combination with tirelizumab and platinum-containing dual-agent chemotherapy in previously untreated patients with advanced non-small cell lung cancer who are EGFR/ALK negative. The study is divided into 2 phases.


Clinical Trial Description

Phase 1 is a preliminary exploration of safety and efficacy. The safety and efficacy of the regimen was assessed in the 10 patients enrolled for interim analysis. Phase 2 will continue to expand the sample size to assess the efficacy and safety of the regimen, with 20 patients planned to be enrolled. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06136910
Study type Interventional
Source Fujian Cancer Hospital
Contact Zhiyong He, Master
Phone +8613805086391
Email liyunmiao462@163.com
Status Recruiting
Phase Phase 1/Phase 2
Start date May 9, 2023
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT00254319 - Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) Phase 2